HSE Manager
Oncoinvent AS
- Frist Snarest
Vil du være med å bygge Life Science industrien i Norge?
Oncoinvent AS is looking for a HSE (Health, Safety & Environmental) Manager to lead the HSE effort at Oncoinvent and to further develop the HSE program and culture.
The primary objective of the HSE manager is to ensure that Oncoinvent operates in a safe and compliant manner, both with respect to health and safety of its employees and the environment it operates.
This position is an exciting opportunity to work in an innovative and dynamic bio-technology start-up company, to further develop the HSE program and build on the solid HSE culture within the company. The company is performing both R&D, manufacturing and is working with radioactive substances which gives a broad spectrum of challenges.
The candidates should be looking for the energy and enthusiasm in a start-up company with the ambition to make a difference for patients worldwide.
The position will report to the Chief Executive Officer.
Scope:
- HSE and radiation protection aspects at Oncoinvent’s R&D- and GMP production facility.
- Ergonomic aspects at Oncoinvent’s facility and offices.
- Own, develop and maintain Oncoinvent’s HSE system including radiation protection procedures.
- Establish measurable HSE and radiation protection goals together with Oncoinvent’s leadership.
- Enforce compliance with Oncoinvent’s and Norwegian HSE and radiation protection procedures.
- Facilitate HSE behavioral leadership.
- Facilitate risk assessments and implement mitigating actions for relevant operations.
- Work with Oncoinvent staff to improve and maintain HSE and radiation protection procedures.
- Ensure that Oncoinvent staff is trained in all relevant HSE and radiation protection procedures.
- Ensure that all HSE and radiation protection training is documented.
- Work proactively together with Oncoinvent’s staff to avoid any HMS incidents.
- With the CEO, report incidents to the relevant authorities (Health and Safety Executive, DSA).
- Prepare quarterly reports on the HSE status of the R&D and GMP production operations.
- Together with the CEO, liaise with regulatory authorities.
- Support Oncoinvent during inspections and audits from regulatory bodies.
- Support Oncoinvent in responding to questions from regulatory bodies.
- Support production, QC and QA in the investigation and closure of deviations.
- Support production, QC and QA in the implementation of Corrective and Preventative Actions (CAPA).
Qualifications and experience:
The holder of this position should have the following documented qualifications and experience:
- As a minimum M.Sc. or equivalent education or experience is a requirement.
- Experience as a HSE responsible; preferably in a similar type of company or organization.
- Experience with radiation and hazardous chemicals and experience with chemical laboratories or manufacturing is an advantage.
- Fluency in English and preferably working knowledge of Norwegian.
- The successful candidate has a demonstrated ability to deliver on challenging goal and have a systematic approach with relevant scientific competence. The ability to network, communicate- and perform team work well will be appreciated.
Om arbeidsgiveren
The Oncoinvent team consists of 32 employees and the company anticipates further growth.
In December 2017 Oncoinvent finished building a state-of-the-art manufacturing facility to produce drug product intended for use in pre-clinical and clinical trials. Clinical trials for Oncoinvent’s lead product, Radspherin®, started in 2020. For further details on Oncoinvent see www.oncoinvent.com.
The facility received a GMP certificate from the Norwegian Medical Agency in February of 2019. The approval provides the company with the necessary flexibility and capacity for manufacturing clinical trial material for both patients and trial sites, as well as developing the company further.
The company’s lead product candidate Radspherin® is a novel alpha-emitting radioactive microsphere suspension designed for treatment of micro-metastatic cancers in body cavities. The radium-224 based therapeutic, Radspherin® has shown strong and consistent anticancer activity at doses being essentially non-toxic in preclinical studies. It is anticipated that the product can potentially treat several forms of micro-metastatic cancer.
- Nettverk: Facebook, LinkedIn
- Sted: Gullhaugveien 7, 0484 Oslo
- Bransje: Farmasi og legemiddel, Industri og produksjon, Kjemisk industri
- Stillingsfunksjon: HMS, Ledelse, Sikkerhet
Nøkkelord
EHS Manager, HSE Advisor, HSE, HMS Manager
Annonseinformasjon
- FINN-kode 211324867
- Sist endret